Inhibikase Therapeutics, Inc.
IKT
$2.41
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.60% | -28.63% | -6.74% | -20.32% | 27.51% |
| Total Depreciation and Amortization | -- | -- | -100.00% | -2.07% | 90.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.12% | -9.11% | 38.93% | -10.09% | -53.24% |
| Change in Net Operating Assets | 5,965.67% | -112.32% | 119.05% | -560.15% | -64.85% |
| Cash from Operations | -3.18% | -60.45% | 29.05% | -90.03% | -35.84% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 92.66% | -81,362.15% | 99.66% | -392.03% | -53.28% |
| Cash from Investing | 92.66% | -81,362.15% | 99.66% | -392.03% | -53.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -97.32% | 43,016.90% | 688.99% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 200.00% | -- | -- |
| Cash from Financing | -100.50% | -97.33% | 81,058.46% | -521.70% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 79.51% | -188.80% | 355.75% | -1,017.70% | -74.62% |